Cabazitaxel treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) in daily practice - Interim analysis of the non-interventional SCOPE study

被引：0
|
作者：
Bokemeyer, C. [1 ]
Amram, M. -L. [2 ]
Stoiber, F. [3 ]
Gschwend, J. E. [4 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplant, Hamburg, Germany
[2] Univ Hosp, Geneva, Switzerland
[3] Prov Hosp Voecklabruck, Linz, Austria
[4] Univ Hosp Rechts Isar, Munich, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
72
引用
收藏
页码：224 / 224
页数：1
相关论文
共 50 条
  • [21] PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study
    Hammerer, Peter
    Al-Batran, Salah-Eddin
    Windemuth-Kieselbach, Christine
    Keller, Martin
    Hofheinz, Ralf-Dieter
    WORLD JOURNAL OF UROLOGY, 2018, 36 (03) : 375 - 381
  • [22] PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study
    Peter Hammerer
    Salah-Eddin Al-Batran
    Christine Windemuth-Kieselbach
    Martin Keller
    Ralf-Dieter Hofheinz
    World Journal of Urology, 2018, 36 : 375 - 381
  • [23] Cabazitaxel for the treatment of castration-resistant prostate cancer
    Agarwal, Neeraj
    Sonpavde, Guru
    Sartor, Oliver
    FUTURE ONCOLOGY, 2011, 7 (01) : 15 - 24
  • [24] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [25] Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study
    Delanoy, Nicolas
    Robbrecht, Debbie
    Eisenberger, Mario
    Sartor, Oliver
    de Wit, Ronald
    Mercier, Florence
    Geffriaud-Ricouard, Christine
    de Bono, Johann
    Oudard, Stephane
    CANCERS, 2021, 13 (06) : 1 - 13
  • [26] QoLiTime: Quality-of-Life (QoL) analysis of patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel in daily clinical practice
    Hofheinz, R. D.
    Al-Batran, S. E.
    Windemuth-Kieselbach, C.
    Hammerer, P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S499 - S499
  • [27] Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).
    Clement-Zhao, Alice
    Auvray, Marie
    Verret, Benjamin
    Vano, Yann Alexandre
    Angelergues, Antoine
    Oudard, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [28] Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Schnadig, Ian D.
    Bhor, Menaka
    Vogelzang, Nicholas J.
    Hennessy, Daniel
    Nicacio, Leonardo V.
    Berry, William R.
    Hutson, Thomas E.
    Fleming, Mark T.
    Cowey, C. Lance
    Saravanan, Shanmugapriya
    Dhanda, Rahul
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [29] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Bilusic, Marijo
    Karzai, Fatima
    Cordes, Lisa M.
    Strauss, Julius
    Schlom, Jeffrey
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Cabazitaxel in patients with castration-resistant prostate cancer
    Falcao, Gil
    Carneiro, Cabrita
    Pinheiro, Luis Campos
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 25 - 25
12345